Semax dosage protocol

What the compound is

Semax is a synthetic heptapeptide, an analog of the ACTH(4-7) fragment with a C-terminal Pro-Gly-Pro tripeptide (PMID 40692165, PMID 19633950). It is considered a neuroactive peptide (PMID 41490200) and an ACTH-like peptide (PMID 39767736). Semax has been studied for its potential applications in areas such as neuroprotection and healthy aging (PMID 42021992, PMID 41490200).

How it is thought to work

Semax is believed to enhance brain-derived neurotrophic factor (BDNF) and HGF/c-Met pathways, which are critical to neuroplasticity (PMID 41490200). In animal studies, Semax has been shown to activate the transcription of neurotrophins (such as BDNF, NT-3, NGF) and their receptor genes (TrkA, TrkB, TrkC) in the cortex of rats after cerebral ischemia (PMID 19633950). It selectively affected these transcriptions in ischemic rat cortex (PMID 19633950). Semax also appears to target the μ-opioid receptor gene Oprm1, which in turn regulates ubiquitin specific protease USP18, leading to deubiquitination of FTO protein and potential functional recovery (animal study, PMID 40692165). It has been observed to compensate rat brain gene expression profiles disrupted by ischemia (animal study, PMID 39767736).

What laboratory and animal studies report

In female mice with spinal cord injury (SCI), Semax promoted functional recovery and inhibited lysosomal membrane permeabilization (LMP)-related pyroptosis by decreasing oxidative stress (animal study, PMID 40692165). In a rat model of Parkinson's disease-like parkinsonism induced by 6-OHDA, Semax did not affect motor activity or passive defensive behavior (animal study, PMID 28702721). Studies in rats subjected to cerebral ischemia reported that Semax significantly reduced expression distortions for genes associated with immune and neurosignaling pathways (animal study, PMID 39767736). Neurogenesis-, angiogenesis-, protein kinase- and growth factor-related differentially expressed genes were revealed under Semax action (animal study, PMID 39767736). Preclinical studies show promise for Semax, for instance, in neuroprotection (PMID 42021992).

Human evidence so far

A study involving 52 healthy participants investigated the effects of Semax on whole-brain resting-state functional connectivity (FC) (human study, PMID 32342318). This study found between-group and between-condition differences in FC between the right amygdala and regions in the fusiform, inferior and middle temporal, and parahippocampal gyri (human study, PMID 32342318). This allowed for defining both general and specific effects of Semax on FC between the right amygdala and the right temporal cortex (human study, PMID 32342318). While preclinical studies are promising, there is a current lack of extensive clinical trials for many peptides, including Semax, regarding their orthopedic or healthy aging applications (PMID 41490200, PMID 42021992).

Open questions and limitations

Significant knowledge gaps include optimal dosing regimens, effects of combination therapies, and biomarkers for monitoring efficacy (PMID 42021992). Rigorous validation through well-designed clinical trials is needed to establish the safety and efficacy of investigational peptides like Semax for healthspan extension (PMID 42021992). The pattern of Semax's action on the transcriptome in animal models depends on the time elapsed after cerebral ischemia, suggesting the importance of timing in therapeutic applications (animal study, PMID 39767736).

Key terms explained

**Neuroplasticity:** The ability of the brain to change and adapt (PMID 41490200).

**Neurotrophins:** Proteins that support the survival, development, and function of neurons (PMID 19633950).

**Ischemic stroke:** A condition resulting from a disruption of cerebral blood flow (PMID 39767736).

**Functional connectivity (FC):** Measures the statistical dependencies between different brain regions (PMID 32342318).

**Lysosomal membrane permeabilization (LMP):** Damage to the membranes of lysosomes, which are cellular organelles involved in waste breakdown (PMID 40692165).

**Deubiquitination:** The process of removing ubiquitin molecules from a protein (PMID 40692165).